Related Experiment Videos
Malignant hyperthermia during prolonged surgery for tumour resection
1Department of Anaesthesia, Western Infirmary, Glasgow, UK.
European Journal of Anaesthesiology
|April 2, 1998
Summary
Malignant hyperthermia (MH) can present subtly during anesthesia, with gradual increases in heart rate and PETCO2, not always muscle rigidity. Early consideration of MH is crucial for unexplained tachycardia or rising PETCO2 during surgery.
Area of Science:
- Anesthesiology
- Pharmacology
- Critical Care Medicine
Background:
- Malignant hyperthermia (MH) is a rare, life-threatening pharmacogenetic disorder of skeletal muscle.
- It is typically triggered by volatile anesthetics and succinylcholine in susceptible individuals.
- Prompt recognition and treatment are critical for patient survival.
Observation:
- This case describes a delayed and atypical onset of malignant hyperthermia during prolonged anesthesia for tumor resection.
- The patient exhibited a gradual rise in heart rate and end-tidal carbon dioxide (PETCO2) without muscle rigidity.
- Other concurrent medical conditions complicated the clinical presentation and diagnosis.
Findings:
- The malignant hyperthermia episode responded rapidly to dantrolene treatment, allowing surgery to continue.
- A potential recrudescence of MH symptoms was observed 18 hours post-initial event.
- Unexplained tachycardia and rising PETCO2 in the perioperative period should raise suspicion for MH.
Implications:
- This case highlights the importance of considering atypical presentations of malignant hyperthermia.
- Anesthesiologists should maintain a high index of suspicion for MH even without classic signs like muscle rigidity.
- Early diagnosis and intervention are key to managing malignant hyperthermia and improving patient outcomes.